Core Viewpoint - The company announces the resignation of director Zhao Chao due to personal reasons, effective October 17, 2025, with his original term set to end on June 28, 2027 [1] Group 1 - Zhao Chao will continue to serve as the president of the company despite his resignation from the board [1] - The company will expedite the process of selecting a new director to fill the vacancy left by Zhao Chao [1] - The company expresses gratitude for Zhao Chao's contributions during his tenure [1]

Core Viewpoint - The announcement details a technical service contract signed between Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. and WuXi AppTec Co., Ltd. to enhance drug development capabilities and reduce clinical trial time and costs, which will not adversely affect the company's financial status or operational results [16]. Group 1: Contract Details - The total amount of the contract is 10,800,000.00 yuan, including a 6% tax, with payments to be made in installments as per the contract terms [3]. - The contract is valid for three years, starting from the date of signing, and will automatically extend until the completion of the project if it is not finished by the expiration date [9]. - All technical service results generated under this contract will belong to the company, which retains the rights to apply for patents [4]. Group 2: Parties Involved - Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of the company, holding 97.9545% of its shares, with a registered capital of 440 million yuan [10][11]. - WuXi AppTec Co., Ltd. has a registered capital of 1.05 billion yuan and specializes in drug development services [13]. Group 3: Financial Impact - The contract is expected to enhance the company's drug research and development capabilities, potentially leading to more efficient clinical trials and cost savings [16]. - The financial data of Sichuan Luzhou Buchang indicates total assets of 234,047.98 million yuan and a net asset of 21,929.81 million yuan as of June 30, 2025 [13].

Group 1: Corporate Leadership Changes - Fuyao Glass's chairman, Cao Dewang, has submitted his resignation but will continue to serve as a director and hold positions in some subsidiaries. His son, Cao Hui, has been elected as the new chairman [1] Group 2: Corporate Transactions - TBEA's subsidiary plans to acquire a 74.19% stake in Shuguang Cable for 946 million yuan to enhance its market share in high-end cable products [2] - Zhiguan Electric intends to purchase minority stakes in its subsidiary, Zhiguan Energy Storage, through a combination of share issuance and cash payment [5] - Yiyi Co. plans to invest 70.2 million yuan in a venture capital fund to strengthen its investment layout in the pet industry [6] Group 3: Corporate Performance - Rongzhi Rixin expects a net profit increase of 871.3% to 908.09% year-on-year for the first three quarters, driven by growth in the power, petrochemical, and non-ferrous industries [7] - Taihe New Materials' subsidiary, Minshida, reported a 28.88% increase in net profit year-on-year for the first three quarters [9] - Fuyao Glass reported a 28.93% increase in net profit year-on-year for the first three quarters, with a revenue growth of 17.62% [10] - Chunfeng Power's net profit increased by 30.89% year-on-year for the first three quarters, attributed to steady business growth [11] - Guobang Pharmaceutical's net profit grew by 23.17% year-on-year in the third quarter, despite a slight decline in revenue [12] - Tianan New Materials reported a 31.12% increase in net profit year-on-year for the third quarter, driven by growth in its subsidiaries [13] - Guangsheng Nonferrous expects to turn a profit in the first three quarters, with a projected net profit of 100 million to 130 million yuan, benefiting from rising rare earth market prices [14] - Aobi Zhongguang anticipates a net profit of approximately 108 million yuan for the first three quarters, marking a return to profitability [15] Group 4: Share Buybacks and Reductions - Jinchuan Group's shareholder, China Railway, plans to reduce its stake by up to 3% [16] - Yinlong Co.'s actual controller plans to reduce its stake by up to 1.96% [17] - Action Education's shareholders plan to collectively reduce their holdings by up to 230,000 shares [18] - Zhijiang Bio plans to repurchase shares worth between 60 million and 120 million yuan for employee stock ownership plans [19] Group 5: Significant Contracts - Buchang Pharmaceutical's subsidiary signed a technical service contract with WuXi AppTec for 10.8 million yuan, enhancing its drug development capabilities [20] - Zhongchao Holdings' subsidiary is involved in a national key project on new materials, focusing on high-temperature alloy casting [20]

（文章来源：证券日报） 证券日报网讯 10月16日晚间，步长制药发布公告称，近日，公司控股子公司四川泸州步长生物制药有 限公司与苏州药明康德新药开发有限公司（简称"药明康德"）签订《技术服务合同》，委托药明康德进 行药代动力学和毒理学试验项目。 ...

证券日报网讯 10月16日晚间，步长制药发布公告称，公司于2025年10月16日与成都农村商业银行股份 有限公司泸州分行（简称"成都农村商业银行泸州分行"）签订《保证合同》，为公司控股子公司四川泸 州步长生物制药有限公司（简称"泸州步长"）与成都农村商业银行泸州分行签订的《流动资金借款合 同》提供2，000万元连带责任保证。 （文章来源：证券日报） ...

Core Viewpoint - Company signed a technical service contract with WuXi AppTec to enhance drug development capabilities and reduce clinical trial time and costs [1] Group 1 - Sichuan Luzhou Buchang Pharmaceutical Co., Ltd. (subsidiary of Buchang Pharmaceutical) entered into a contract with WuXi AppTec for pharmacokinetics and toxicology testing [1] - The collaboration is expected to expand the company's drug research and development capacity and scope [1] - The agreement aims to ensure the smooth progress of projects while saving time and costs associated with clinical trials [1]

Core Viewpoint - Company announced a collaboration with WuXi AppTec to enhance its drug development capabilities and reduce clinical trial time and costs [1] Group 1 - Company’s subsidiary, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., signed a technical service contract with WuXi AppTec [1] - The collaboration is expected to expand the company's drug research and development capacity [1] - The agreement aims to ensure the smooth progress of projects by saving time and costs associated with clinical trials [1]

每经头条（nbdtoutiao）——"短板"正在被一块块补上！直击湾芯展："中国芯"是怎么炼成的 （记者 张明双） 每经AI快讯，步长制药（SH 603858，收盘价：18.01元）10月16日晚间发布公告称，近日，山东步长制 药股份有限公司控股子公司四川泸州步长生物制药有限公司与苏州药明康德新药开发有限公司签订《技 术服务合同》，委托药明康德进行药代动力学和毒理学试验项目。本次泸州步长与第三方签订《技术服 务合同》，有利于扩大公司药品研发能力和范围，一定程度上节约了公司药品临床试验的时间和成本， 保障项目的顺利进行。本事项不会对公司财务状况和经营成果产生不利影响。 截至发稿，步长制药市值为190亿元。 ...

Group 1 - The core point of the announcement is that Buchang Pharma has provided guarantees totaling approximately RMB 2.18 billion, which accounts for 21.34% of the company's audited net assets as of the end of 2024 [1] - As of the announcement date, Buchang Pharma's market capitalization is reported to be RMB 19 billion [2]

山东步长制药股份有限公司 关于为公司控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603858 证券简称：步长制药 公告编号：2025-193 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 四川泸州步长生物制药有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 2,000 万元 | | | | 担保对象 | 实际为其提供的担保余额 | 58,203 万元 | | | | | 是否在前期预计额度内 | 是 □否 | | □不适用：_________ | | | 本次担保是否有反担保 | 是 ☑否 | | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 218,030.79 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 21.34 | | 特别风险提示 ...